Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MAP kinase kinase kinase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: MAP kinase kinase kinase. Displaying page 1 of 1.
    EudraCT Number: 2005-003495-38 Sponsor Protocol Number: PA18439 Start Date*: 2005-11-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) DE (Prematurely Ended) GB (Completed) EE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003694-25 Sponsor Protocol Number: PA18604 Start Date*: 2006-01-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Ensayo randomizado, doble ciego, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia y seguridad de RO4402257 como monoterapia en comparación con la monoterapia de metotrexato ...
    Medical condition: Artritis Reumatoide Rheumatoid Arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-004017-17 Sponsor Protocol Number: RR11/9965 Start Date*: 2013-04-08
    Sponsor Name:The University of Leeds
    Full Title: Prospective, Single-centre, Open-Label, Randomised, Pilot Study Assessing the changes in expression of JAK-STAT and Speed & Depth of Remission Induced by Tocilizumab & Methotrexate Combination and ...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006686-32 Sponsor Protocol Number: EC07/90573 Start Date*: 2008-05-22
    Sponsor Name:FUNDACIÓN INVESTIGACIÓN BIOMEDICA DEL HOSPITAL CLINICO SAN CARLOS
    Full Title: Identificación de biomarcadores proteicos asociados a resistencia a la aspirina y a tienopiridinas en pacientes con cardiopatía isquémica establecida. (ESTUDIO BIRAT). Identification of new protei...
    Medical condition: To determine proteins in plasma, leukocytes and platelets associated with aspirin resistance syndrome in stable coronary artery disease patients that may allow us to identify them.It is probably th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000657-50 Sponsor Protocol Number: PM1116197 Start Date*: 2014-05-27
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197)...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10003723 Attack coronary LLT
    16.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    16.1 10007541 - Cardiac disorders 10071111 Non ST segment elevation acute coronary syndrome LLT
    16.1 100000004848 10041894 ST segment elevation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Prematurely Ended) IT (Completed) DE (Completed) BE (Completed) SK (Completed) DK (Completed) ES (Completed) NO (Completed) GB (Completed) CZ (Completed) HU (Completed) EE (Completed) GR (Prematurely Ended) PL (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-004388-11 Sponsor Protocol Number: EIP-VX17-745-304 Start Date*: 2018-10-11
    Sponsor Name:EIP Pharma Inc
    Full Title: A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2022-002874-10 Sponsor Protocol Number: 2022-3545 Start Date*: 2022-12-16
    Sponsor Name:Gustave Roussy
    Full Title: Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma
    Medical condition: Newly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002155-17 Sponsor Protocol Number: LAP105594 Start Date*: 2008-04-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positiv...
    Medical condition: Advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumour cells
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001072-21 Sponsor Protocol Number: MKN106762 Start Date*: 2006-08-08
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A double-blind placebo-controlled study of the efficacy and safety of the P38 Map Kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma
    Medical condition: Neuropathic pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011904-47 Sponsor Protocol Number: SoraDox2009 Start Date*: 2010-11-18
    Sponsor Name:Ethik-Kommission der Medizinischen Fakultät der Martin-Luther-Universität Halle Wittenberg
    Full Title: Sorafenib plus doxorubicin versus sorafenib alone for the treatment of advanced hepatocellular carcinoma: a randomized phase II trial
    Medical condition: Advanced hepatocellular carcinoma (HCC) stage C (or better) according to BCLC classification restricted to Child-Pugh class A/B (5-7 points).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002855-25 Sponsor Protocol Number: EIP-VX00-745-302 Start Date*: 2015-03-11
    Sponsor Name:EIP Pharma, LLC
    Full Title: A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic ...
    Medical condition: Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011200-39 Sponsor Protocol Number: PKI113009 Start Date*: 2010-01-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared t...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    12.0 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-004612-12 Sponsor Protocol Number: 0811601 Start Date*: 2008-11-06
    Sponsor Name:CHU TOULOUSE
    Full Title: Existe t-il une sensibilité accrue à l’hormone de croissance chez les enfants présentant un syndrome de Prader-Willi ?
    Medical condition: - syndrome de Prader-Willi - déficit en hormone de croissance
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036476 Prader-Willi syndrome LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001546-34 Sponsor Protocol Number: EADO_VC_NEO_1 Start Date*: 2014-10-02
    Sponsor Name:University Hospital Tübingen
    Full Title: Neoadjuvant treatment with the combination of Vemurafenib, Cobimetinib and Atezolizumab in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: A single arm...
    Medical condition: Patients with hardly resectable/unresectable limited metastasis in malignant melanoma stages IIIC/IV (American Joint Committee on Cancer (AJCC) 2010) carrying the BRAF V600 mutation, in order to ac...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 21:00:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA